



Dr Vamsi Krishna Yenamandra

Genomics · Immunology · Dermatology

CLINICIAN PROFILE

GENOMICS · IMMUNOLOGY · RARE DISEASE

Dr Vamsi Krishna Yenamandra

MBBS · MD-PhD (AIIMS) · Postdoc Groningen & Stanford

Director, Genomics and Immunology · Professor of Dermatology

Families come after years without a name for the illness, after a medicine that did not fit, or because a rare skin or immune disease has not found a centre that can both sequence and treat. Dr Vamsi Krishna Yenamandra is a physician-scientist and dermatologist. He trained at AIIMS, New Delhi, then at UMC Groningen and Stanford, led topical gene therapy work for epidermolysis bullosa, and developed AlphaSeq, now used in 96 countries. At SMSIMSR he directs Genomics and Immunology.

Director, Genomics and Immunology

Sri Madhusudan Sai Institute of Medical Sciences and Research

Sathya Sai Grama, Muddenahalli — 30 minutes from Bangalore International Airport

Sequence first. Then choose the therapy.

The laboratory on this campus runs an Illumina MiSeq i100 with interpretation on site. Gene panels, whole-exome and whole-genome sequencing, pharmacogenomics, immune profiling, biologics and selected cell-based therapy including CAR-T sit in one department.

What he sees patients for

International families most often come for an undiagnosed rare disease, a genodermatosis such as epidermolysis bullosa, an autoimmune skin or joint disease that has failed standard treatment, or a pharmacogenomic question before a long medicine list is started.

Rare and undiagnosed disease	Ending a long diagnostic odyssey — targeted panels, whole-exome and whole-genome sequencing with counselling on site
Pharmacogenomics	The right drug, the right dose — before a medicine is started or after one has failed
Precision immunology	Immune profiling and a biologic or cell-based path — rheumatoid arthritis, lupus, psoriasis, vitiligo, pemphigus
Epidermolysis bullosa	NGS for one of the world's largest EB cohorts. Gene and cell therapy work that began at Stanford and continues here
Trials and repurposing	Cord-blood stem cells, topical gene therapy (Krystal / Vyjuvek), antisense oligonucleotides, selected biologics

Why families can feel steady in his care

► AIIMS, Groningen, Stanford

MBBS, Dr NTR University of Health Sciences. MD-PhD, AIIMS New Delhi. Post-doctoral fellowship, UMC Groningen. Postdoc, Stanford University. Then CSIR-IGIB and Tata IISc.

► A test and a therapy that travelled

AlphaSeq, now deployed in 96 countries. Pioneered next-generation sequencing for one of the world's largest epidermolysis bullosa cohorts. Work on the first FDA-approved topical gene therapy (Krystal / Vyjuvek).

► Recognised for the science

CDA Trophy, British Association of Dermatologists, 2015. Young Dermatologist, IADVL, 2016. Future Leader of Dermatology, EADV-ESDR, 2018. AIIMS Excellence Awards, 2014–2018.

Credentials

Present appointment	Director, Genomics and Immunology Professor of Dermatology Sri Madhusudan Sai Institute of Medical Sciences and Research (SMSIMSR), Sathya Sai Grama, Muddenahalli
----------------------------	--



Qualifications	MBBS — Dr NTR University of Health Sciences MD-PhD — AIIMS, New Delhi Post-doctoral fellowship — UMC Groningen, Netherlands Postdoc — Stanford University, USA
Earlier posts	Assistant Professor — CSIR-IGIB and Tata IISc
Practice	Rare and undiagnosed disease genomics Pharmacogenomics Precision immunology and biologics Epidermolysis bullosa and other genodermatoses Cell and gene therapy · Clinical trials and drug repurposing
On this campus	Illumina MiSeq i100 with on-site interpretation Targeted panels, whole-exome and whole-genome sequencing Immune profiling — flow cytometry and cytokine assays Selected cell-based therapy, including CAR-T
Recognition	CDA Trophy 2015 — British Association of Dermatologists Young Dermatologist 2016 — IADVL Future Leader of Dermatology 2018 — EADV-ESDR AIIMS Excellence Awards 2014–2018 DSMB — University Hospital Salzburg DBT UMMID Technical Expert Committee APACMED — NITI Aayog member

A short note on coming to clinic

Bring previous genetic reports if you have them, a list of medicines, photographs of the skin if relevant, and a plain account of how long the illness has gone unnamed. The first visit is an assessment and a written plan — not an automatic test or infusion. This note is to help you choose a team. It is not a substitute for a consultation.

Sri Madhusudan Sai Institute of Medical Sciences and Research

Sathya Sai Grama, Muddenahalli, Chikkaballapura – 562 101, Karnataka

30 minutes from Bangalore International Airport

WhatsApp / call

Shobhna Gupta +91 97418 42802 · shobhna.gupta@smsimsr.org

Sujith Chathoth +91 70128 49103 · sujith.chathoth@smsimsr.org

internationalpatients@smsimsr.org · www.smsimsr.org